Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letās hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
Genmab just dropped $8 billion on Merus like itās Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexāGenmabās basically saying, 'Weāll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeāyouāre still hoping it doesnāt break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Linkin Parkās New Tour: Same Band, New Lead Singer, Twice The Confusion
Volunteer Battles Fire That Roasts His Own Home, Because Why Not
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Amazon: Now Selling Groceries and Your Impulse Warehouse Panic
Billion-Dollar Hedge Fundās Head Trader Quits To Take 'Career Break,' Market Shrugs
Billionaire Bros Move T-Rex LLC Out of California to Avoid Paying Taxes; Dinosaur Surprised
Grandfather Gifts $1,500 with Guest Star Role for Financial Advisor
Facebook Exec Jumps Off Career Cliff to Build Giant iPhone Flop
